- call +1-201-465-4211
- email sales@mrinsights.biz
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that explicitly targets enzymes responsible for inflammation and pain namely cyclooxygenase-2 and COX-2.
Scope of the Report:
This report focuses on the Etoricoxib Intermediate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Some of the NSAIDs can be used in a single dose to treat various types of pain; it can also be used for post-surgical pains.
The worldwide market for Etoricoxib Intermediate is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Bayer
Novacap
Abbott
Pfizer
Geri-Care
Perrigo
Kopran
Merck
Sun Pharmaceutical
GlaxoSmithKline
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
n-House Manufacturing
Contract Manufacturing Organizations
Market Segment by Applications, can be divided into
Rheumatoid Arthritis
Psoriatic Arthritis
Osteoarthritis
Ankylosing Spondylitis
Chronic Low Back Pain
Acute Pain
Others
There are 15 Chapters to deeply display the global Etoricoxib Intermediate market.
Chapter 1, to describe Etoricoxib Intermediate Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Etoricoxib Intermediate, with sales, revenue, and price of Etoricoxib Intermediate, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Etoricoxib Intermediate, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Etoricoxib Intermediate market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Etoricoxib Intermediate sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Etoricoxib Intermediate Introduction
1.2 Market Analysis by Type
1.2.1 n-House Manufacturing
1.2.2 Contract Manufacturing Organizations
1.3 Market Analysis by Applications
1.3.1 Rheumatoid Arthritis
1.3.2 Psoriatic Arthritis
1.3.3 Osteoarthritis
1.3.4 Ankylosing Spondylitis
1.3.5 Chronic Low Back Pain
1.3.6 Acute Pain
1.3.7 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Etoricoxib Intermediate Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bayer Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novacap
2.2.1 Business Overview
2.2.2 Etoricoxib Intermediate Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novacap Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Abbott
2.3.1 Business Overview
2.3.2 Etoricoxib Intermediate Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Abbott Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Etoricoxib Intermediate Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Pfizer Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Geri-Care
2.5.1 Business Overview
2.5.2 Etoricoxib Intermediate Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Geri-Care Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Perrigo
2.6.1 Business Overview
2.6.2 Etoricoxib Intermediate Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Perrigo Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Kopran
2.7.1 Business Overview
2.7.2 Etoricoxib Intermediate Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Kopran Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Merck
2.8.1 Business Overview
2.8.2 Etoricoxib Intermediate Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Merck Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Sun Pharmaceutical
2.9.1 Business Overview
2.9.2 Etoricoxib Intermediate Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Sun Pharmaceutical Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 GlaxoSmithKline
2.10.1 Business Overview
2.10.2 Etoricoxib Intermediate Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 GlaxoSmithKline Etoricoxib Intermediate Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Etoricoxib Intermediate Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Etoricoxib Intermediate Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Etoricoxib Intermediate Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Etoricoxib Intermediate Manufacturer Market Share in 2017
3.3.2 Top 6 Etoricoxib Intermediate Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Etoricoxib Intermediate Market Analysis by Regions
4.1 Global Etoricoxib Intermediate Sales, Revenue and Market Share by Regions
4.1.1 Global Etoricoxib Intermediate Sales and Market Share by Regions (2013-2018)
4.1.2 Global Etoricoxib Intermediate Revenue and Market Share by Regions (2013-2018)
4.2 North America Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
4.3 Europe Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
4.5 South America Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
5 North America Etoricoxib Intermediate by Countries
5.1 North America Etoricoxib Intermediate Sales, Revenue and Market Share by Countries
5.1.1 North America Etoricoxib Intermediate Sales and Market Share by Countries (2013-2018)
5.1.2 North America Etoricoxib Intermediate Revenue and Market Share by Countries (2013-2018)
5.2 United States Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
5.3 Canada Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
5.4 Mexico Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
6 Europe Etoricoxib Intermediate by Countries
6.1 Europe Etoricoxib Intermediate Sales, Revenue and Market Share by Countries
6.1.1 Europe Etoricoxib Intermediate Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Etoricoxib Intermediate Revenue and Market Share by Countries (2013-2018)
6.2 Germany Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
6.3 UK Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
6.4 France Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
6.5 Russia Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
6.6 Italy Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
7 Asia-Pacific Etoricoxib Intermediate by Countries
7.1 Asia-Pacific Etoricoxib Intermediate Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Etoricoxib Intermediate Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Etoricoxib Intermediate Revenue and Market Share by Countries (2013-2018)
7.2 China Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
7.3 Japan Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
7.4 Korea Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
7.5 India Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
8 South America Etoricoxib Intermediate by Countries
8.1 South America Etoricoxib Intermediate Sales, Revenue and Market Share by Countries
8.1.1 South America Etoricoxib Intermediate Sales and Market Share by Countries (2013-2018)
8.1.2 South America Etoricoxib Intermediate Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
8.3 Argentina Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
8.4 Colombia Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
9 Middle East and Africa Etoricoxib Intermediate by Countries
9.1 Middle East and Africa Etoricoxib Intermediate Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Etoricoxib Intermediate Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Etoricoxib Intermediate Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
9.3 UAE Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
9.4 Egypt Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
9.5 Nigeria Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
9.6 South Africa Etoricoxib Intermediate Sales and Growth Rate (2013-2018)
10 Global Etoricoxib Intermediate Market Segment by Type
10.1 Global Etoricoxib Intermediate Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Etoricoxib Intermediate Sales and Market Share by Type (2013-2018)
10.1.2 Global Etoricoxib Intermediate Revenue and Market Share by Type (2013-2018)
10.2 n-House Manufacturing Sales Growth and Price
10.2.1 Global n-House Manufacturing Sales Growth (2013-2018)
10.2.2 Global n-House Manufacturing Price (2013-2018)
10.3 Contract Manufacturing Organizations Sales Growth and Price
10.3.1 Global Contract Manufacturing Organizations Sales Growth (2013-2018)
10.3.2 Global Contract Manufacturing Organizations Price (2013-2018)
11 Global Etoricoxib Intermediate Market Segment by Application
11.1 Global Etoricoxib Intermediate Sales Market Share by Application (2013-2018)
11.2 Rheumatoid Arthritis Sales Growth (2013-2018)
11.3 Psoriatic Arthritis Sales Growth (2013-2018)
11.4 Osteoarthritis Sales Growth (2013-2018)
11.5 Ankylosing Spondylitis Sales Growth (2013-2018)
11.6 Chronic Low Back Pain Sales Growth (2013-2018)
11.7 Acute Pain Sales Growth (2013-2018)
11.8 Others Sales Growth (2013-2018)
12 Etoricoxib Intermediate Market Forecast (2018-2023)
12.1 Global Etoricoxib Intermediate Sales, Revenue and Growth Rate (2018-2023)
12.2 Etoricoxib Intermediate Market Forecast by Regions (2018-2023)
12.2.1 North America Etoricoxib Intermediate Market Forecast (2018-2023)
12.2.2 Europe Etoricoxib Intermediate Market Forecast (2018-2023)
12.2.3 Asia-Pacific Etoricoxib Intermediate Market Forecast (2018-2023)
12.2.4 South America Etoricoxib Intermediate Market Forecast (2018-2023)
12.2.5 Middle East and Africa Etoricoxib Intermediate Market Forecast (2018-2023)
12.3 Etoricoxib Intermediate Market Forecast by Type (2018-2023)
12.3.1 Global Etoricoxib Intermediate Sales Forecast by Type (2018-2023)
12.3.2 Global Etoricoxib Intermediate Market Share Forecast by Type (2018-2023)
12.4 Etoricoxib Intermediate Market Forecast by Application (2018-2023)
12.4.1 Global Etoricoxib Intermediate Sales Forecast by Application (2018-2023)
12.4.2 Global Etoricoxib Intermediate Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Etoricoxib Intermediate Picture
Table Product Specifications of Etoricoxib Intermediate
Figure Global Sales Market Share of Etoricoxib Intermediate by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
